The estimated Net Worth of Eric Sjogren is at least $449 Tysiąc dollars as of 24 June 2019. Eric Sjogren owns over 21,739 units of Calithera Biosciences Inc stock worth over $3,603 and over the last 10 years he sold CALA stock worth over $0. In addition, he makes $445,144 as Senior Vice President - Drug Discovery at Calithera Biosciences Inc.
Sign up
Eric Sjogren CALA stock SEC Form 4 insiders trading
Eric has made over 2 trades of the Calithera Biosciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 21,739 units of CALA stock worth $20,869 on 24 June 2019.
The largest trade he's ever made was exercising 21,739 units of Calithera Biosciences Inc stock on 24 June 2019 worth over $20,869. On average, Eric trades about 2,409 units every 28 days since 2015. As of 24 June 2019 he still owns at least 72,057 units of Calithera Biosciences Inc stock.
You can see the complete history of Eric Sjogren stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Eric Sjogren biography
Dr. Eric B. Sjogren Ph.D. serves as Senior Vice President - Drug Discovery of the Company. Dr. Sjogren joined Calithera in June 2010 and currently serves as our Senior Vice President of Drug Discovery. From 2003 to 2009, Dr. Sjogren was Vice President and Head of Medicinal Chemistry at Roche Palo Alto, LLC, where he directed a small molecule drug discovery team in the areas of inflammation, virology and central nervous system disorders. Dr. Sjogren received a B.A. in Chemistry from the University of California, San Diego and a Ph.D. in Chemistry from Harvard University.
What is the salary of Eric Sjogren?
As the Senior Vice President - Drug Discovery of Calithera Biosciences Inc, the total compensation of Eric Sjogren at Calithera Biosciences Inc is $445,144. There are 6 executives at Calithera Biosciences Inc getting paid more, with Susan Molineaux having the highest compensation of $2,209,840.
How old is Eric Sjogren?
Eric Sjogren is 63, he's been the Senior Vice President - Drug Discovery of Calithera Biosciences Inc since 2010. There are 6 older and 16 younger executives at Calithera Biosciences Inc. The oldest executive at Calithera Biosciences Inc is H. Ward Wolff, 71, who is the Independent Director.
What's Eric Sjogren's mailing address?
Eric's mailing address filed with the SEC is C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD. #200, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Calithera Biosciences Inc
Over the last 10 years, insiders at Calithera Biosciences Inc have traded over $23,150,153 worth of Calithera Biosciences Inc stock and bought 7,859,025 units worth $49,155,939 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Partners Gp, L.L.C.... oraz Deepika Pakianathan. On average, Calithera Biosciences Inc executives and independent directors trade stock every 43 days with the average trade being worth of $8,053. The most recent stock trade was executed by Deepika Pakianathan on 27 January 2023, trading 121,333 units of CALA stock currently worth $47,320.
What does Calithera Biosciences Inc do?
calithera is focused on discovering and developing first-in-class small molecule drugs that slow tumor growth through controlling key metabolic pathways in the tumor and immune cells. tumor metabolism and tumor immunology are promising new interrelated fields for cancer drug discovery. recent clinical successes have demonstrated the potential to slow abnormal cell growth and create fundamentally new therapies for cancer patients. our investigational onco-metabolism medicines take advantage of the different metabolic requirements of tumor cells and cancer-fighting immune cells. calithera’s discovery and development efforts are focused on solid tumors for which new treatments are urgently needed. we are currently developing our lead candidate in phase 2 trials in patients with renal cell carcinoma, triple negative breast cancer. targeting cancer, differently. our onco-metabolism approach brings an enhanced perspective to cancer.
What does Calithera Biosciences Inc's logo look like?
Complete history of Eric Sjogren stock trades at Calithera Biosciences Inc
Calithera Biosciences Inc executives and stock owners
Calithera Biosciences Inc executives and other stock owners filed with the SEC include:
-
Susan Molineaux,
President, Chief Executive Officer, Co-Founder, Director -
Sumita Ray,
Senior Vice President, Chief Compliance Officer, General Counsel -
Keith Orford,
Chief Medical Officer -
Curtis Hecht,
Chief Business Officer -
Dr. Susan M. Molineaux Ph.D.,
Founder, CEO, Pres & Director -
Christopher Molineaux,
Senior Vice President - Development -
Eric Sjogren,
Senior Vice President - Drug Discovery -
Deepa Pakianathan,
Lead Independent Director -
H. Ward Wolff,
Independent Director -
Jean George,
Independent Director -
Sunil Agarwal,
Independent Director -
Suzy Jones,
Independent Director -
Blake Wise,
Independent Director -
Jonathan Drachman,
Independent Director -
Scott Garland,
Independent Director -
Jennifer McNealey,
Vice President, Investor Relations and Strategy -
Francesco Parlati,
Vice President - Research -
Stephanie Wong,
Vice President - Finance, Secretary -
Dr. Allison Dillon Ph.D.,
Sr. VP of Commercial & Portfolio Strategy -
Dr. Susan B. Demo Ph.D.,
Sr. VP of R&D Operations -
Matthew Gross,
Head of Bus. Devel. -
Dr. Emil T. Kuriakose M.D.,
Chief Medical Officer -
Frank Parlati,
Sr. VP of Research -
Dr. Christopher J. Molineaux Ph.D.,
Sr. VP of Devel. -
Dr. Eric B. Sjogren,
Sr. VP of Drug Discovery -
Sumita Ray J.D.,
Chief Legal & Admin. Officer -
Stephanie Wong,
CFO & Sec. -
Capital Partners Gp, L.L.C....,
-
William D. Waddill,
SENIOR VP & CFO -
Mark K Bennett,
SR. VP, RESEARCH -
Venture Partners Ix Lp Morg...,
10% owner -
Management Partners Viii, L...,
-
Technology Ventures Viii Lp...,
-
Ralph E Christoffersen,
Director -
Partners L P/Ilbiotechnolog...,
-
Pharmaceutical Co Ltd Taked...,
-
Deepika Pakianathan,
Director -
Emil Kuriakose,
CHIEF MEDICAL OFFICER